Summary
Takeda Pharmaceutical Company Limited (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.
Takeda Pharmaceutical Company Limited (4502) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 13
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 14
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 15
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 16
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 17
Takeda Pharmaceutical Company Limited, Medical Devices Deals, 2010 to YTD 2016 19
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 20
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deal Details 40
Asset Purchase 40
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 40
Wako Pure Chemical Industries Acquires Kalypsys System Business Unit Of Kalypsys 41
Venture Financing 42
Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 42
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 43
Cortexyme Raises USD15 Million in Series A Financing Round 45
Univercells Raises USD3.4 Million in Equity Financing Round 47
Encycle Therapeutics Raises USD2 Million in Seed Financing 48
Presage Biosciences Raises Funds through Venture Financing 49
Naurex Raises USD80 Million in Series C Venture Financing 50
Naurex Raises US$25 Million In Venture Financing 52
Hookipa Biotech Raises US$27 Million In Series B Financing 54
Heptares Therapeutics Raises US$21 Million In Series B Financing 56
Redwood Bioscience Raises US$8.6 Million In Venture Financing 58
Naurex Raises US$38 Million In Series B Financing 59
ArmaGen Technologies Raises US$17 Million In Series A Financing 62
Juventas Therapeutics Raises US$22.2 Million In Series B Venture Financing Round 64
LigoCyte Pharmaceuticals Raises US$2 Million In Venture Financing Round 66
Redwood Bioscience Secures Funding From Takeda Ventures 67
LigoCyte Pharma Secures US$5.5 Million In Venture Financing 68
Naurex Secures US$18 Million In Series A Financing Round 69
Fate Therapeutics Secures Venture Financing 71
CellCentric Raises Funds in Series B Financing Round 73
LigoCyte Pharma Raises US$6.5 Million In Venture Financing 74
Domainex Secures Additional Financing 75
Private Equity 76
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 76
Partnerships 77
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 77
Pfizer Japan Terminates Distribution Agreement with Takeda Pharma for Prevenar13 and Benefix 78
Takeda Pharma to Enter into Agreement with Altos Therapeutics 79
Exosome Diagnostics Enters into Agreement with Takeda Pharma 80
TB Alliance and Takeda Pharma Enter into Agreement 81
Takeda Pharma Enters into Agreement with M2Gen 82
Takeda Pharma to Enter into Co-Development Agreement with Ultragenyx Pharma 83
Takeda Pharma Forms Joint Venture with Roivant Sciences 84
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 85
Prosetta Biosciences Enters into Agreement with Takeda Pharma 87
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 88
Teva Pharma and Takeda Pharma Form Joint Venture 89
Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 91
Mersana Therapeutics Enters into Agreement with Takeda 92
Broad Institute Genomic Services Partners with Takeda Pharma 93
Takeda Pharma Enters into Partnership with enGene 94
Takeda Pharma Enters into Research Agreement with NsGene 95
Takeda Pharma Enters into Agreement with Enterome Bioscience 96
Vipergen Enters into Agreement with Takeda Pharma 97
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 98
Takeda Pharma Enters into R&D Agreement with Cour Pharma 99
University College London Enters into Research Agreement with Takeda Pharma 100
Takeda Pharma Enters into Agreement with Nanotherapeutics 101
DNDi Enters into Agreement with Takeda Pharma 102
Takeda Pharma Enters into Agreement with Sanford-Burnham 103
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 104
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 105
CiRA Enters into Co-Development Agreement with Takeda Pharma 106
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 107
Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 108
Mersana Expands Co-Development Agreement with Takeda Pharma 109
Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 110
Presage Biosciences Expands its Research Agreement with Takeda Pharma 111
GE Healthcare Enters into R&D Agreement with Takeda Pharma 112
Intra-Cellular Therapies Terminates Co-Development Agreement with Takeda Pharma 113
GVK Biosciences Forms Joint Venture with Takeda Pharma 114
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 115
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 116
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 117
Mersana Therapeutics Expands Agreement with Takeda Pharma 119
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 120
Takeda Enters into R&D Agreement with University College London 122
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 123
Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 124
Santhera Pharma Terminates Co-Marketing Agreement With Takeda Pharma For Catena 125
Takeda Pharma Enters Into Distribution Agreement With Taisho Pharma 127
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 128
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 129
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 131
Scripps Research Institute Expands Research Agreement With Takeda 132
Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 133
Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 135
Gladstone Enters into Research Agreement with Takeda Pharma 137
Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 138
Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 139
Takeda Pharma Enters Into Research Agreement With BC Cancer Agency 140
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 141
Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 142
Yokogawa Electric Enters Into Co-Marketing Agreement With Wako Pure Chemical Industries For CellVoyager CV7000 143
Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 144
Metabolon Enters Into Co-Development Agreement With Takeda Pharma 145
Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 146
Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 147
CIC bioGUNE Enters into Agreement with Millennium Pharma 148
Takeda Pharma Enters Into Research Agreement With Osaka University 149
Interprotein Enters Into Co-Development Agreement With Takeda Pharma 150
Takeda Pharma International Terminates Co-Promotion Agreement With Merck For Daxas 151
Nycomed Enters Into Co-Marketing Agreement With Orion For Easyhaler 152
Eli Lilly Enters Into Co-Marketing Agreement With Takeda Pharma For Evista 154
Cellectis Bioresearch Enters Into Distribution Agreement With Wako Pure Chemical 156
Nycomed Enters Into Co-Marketing Agreement With Almirall 157
Nycomed Enters Into Distribution Agreement With Almirall, Anika, Bionorica, CSL And Helsinn 158
Dimerix Enters Into Second Research Agreement With Takeda Cambridge 160
Takeda Pharma Enters Into Research Collaboration With Samyang 161
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 162
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 164
KINAXO Biotechnologies Extends Its Collaboration With Takeda San Diego 165
Takeda Enters Into Co-Development Agreement With Covance 166
Takeda Enters Into Co-Development Agreement With Quintiles 167
Pfizer Japan Enters Into Co-Promotion Agreement With Takeda Pharma 168
Pfizer Japan Extends Co-Promotion Agreement With Takeda Pharma 170
Mitsubishi Tanabe Pharma Terminates Its Co-Development Agreement With Nycomed International 171
Evotec Enters Into Collaboration With Takeda Cambridge 172
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 173
Takeda Pharma Enters Into Research Agreement With Sanford-Burnham Medical Research Institute And Florida Hospital 174
Takeda Enters Into Research Agreement With Sage Bionetworks 176
Millenium: The Takeda Oncology Enters Into Research Collaboration With Therasis 177
Takeda Pharma Enters Into Research Agreement With Envoy Therapeutics 178
Takeda Pharma Enters into Co-Development Agreement with Orexigen Therapeutics for Contrave 179
Essen BioScience Enters Into Collaboration Agreement With Nycomed 180
CanBas Terminates Co-Development Agreement With Takeda Pharma 181
Sussex Research Labs Enters Into Distribution Agreement With Wako Pure Chemical Industries For Glycoreagents 183
Nycomed Enters Into Co-Development Agreement With Immuron 184
BC Cancer Agency And Vancouver Prostate Enter Into Agreement With Takeda Pharma 185
Takeda Pharma Enters Into Co-Promotion Agreement With Janssen Pharma 186
Nycomed International Management Enters Into Distribution Agreement With Vifor Pharma For Intravenous Iron Products 188
Nycomed Enters Into Co-Marketing Agreement With Merck 189
Nycomed Enters Into Co-Promotion Agreement With Merck 190
Dimerix Bioscience Enters Into Research Agreement With Takeda Cambridge 192
Takeda Enters Into Co-Marketing Agreement With Janssen Pharma And Janssen Pharmaceutica 193
Aska Pharma Enters Into Co-Marketing Agreement With Nihon Pharma For Minclea 195
NextGen Sciences Enters Into Agreement With Takeda Pharma 196
Ayanda Enters Into Distribution Agreement With Nycomed For CONCORDIX 197
Licensing Agreements 198
Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 198
Takeda Pharma to Enter into Licensing Agreement with Theravance Biopharma for TD-8954 200
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 201
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 202
Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 203
Takeda Pharma Enters into Licensing Agreement with Gencia 204
Takeda Pharma Enters into Licensing Agreement with Kaketsuken 205
Dainippon Sumitomo Pharma to Terminate Licensing Agreement With Takeda Pharma for Lurasidone 206
Takeda Enters into Licensing Agreement with ImmunoGen 208
Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 209
AMAG Pharma Terminates Licensing Agreement with Takeda Pharma for Ferumoxytol 210
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 212
Mersana Exercises Option for License Agreement with Millennium 213
Sucampo Pharma Expands Licensing Agreement with Takeda Pharma 214
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 216
Takeda Pharma Terminates Licensing Agreement with Affymax for Omontys 218
Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 219
Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 220
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 221
Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 223
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 225
Immunomedics Terminates Licensing Agreement With Nycomed For Veltuzumab 227
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 228
Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 230
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 231
Takeda Pharma Terminates Licensing Agreement With Amylin Pharma To Develop Compounds For Obesity 233
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 234
Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 235
Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 236
Galaxy Biotech Terminates Licensing Agreement With Takeda Pharma For HuL2G7 237
Nycomed International Terminates Licensing Agreement With DURECT For POSIDUR 238
Nycomed Enters Into Licensing Agreement With Almirall For Ebastine 240
Nycomed Enters Into Licensing Agreement With Norgine For MOVIPREP 241
Nycomed Enters Into Licensing Agreement With Orion For Easyhaler 243
Takeda Expands Licensing Agreement With Genedata For Proteomics And Metabolomics Experiments 245
Nycomed Enters Into Licensing Agreement With F. Hoffmann-La Roche For Bonviva 246
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 247
Millennium Enters Into Licensing Agreement With Sunesis Pharma 248
Dainippon Sumitomo Enters Into Licensing Agreement With Takeda For Ceftaroline Fosamil 250
Seattle Genetics Extends Licensing Agreement With Millennium 252
DURECT Amends Licensing Agreement With Nycomed 253
Eurand Enters Into Licensing Agreement With Nycomed For ZENPEP 255
Baxter International Expands Its Licensing Agreement With Takeda Pharma 257
Japan Health Sciences Enters into Licensing agreement with Takeda for Human Papillomavirus Vaccine 259
Baxter Enters Into Licensing Agreement With Takeda 260
Nycomed Expands Its Licensing Agreement With Immuron 261
Nycomed Enters Into Licensing Agreement With Immuron 262
Ranbaxy Enters Into Licensing Agreement With Takeda 263
CellCentric Enters Into Licensing Agreement With Takeda Pharma 264
DURECT Amends Development And License Agreement With Nycomed 265
Equity Offering 266
Ultragenyx Pharma to Raise up to USD65 Million in Private Placement of Shares 266
Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 268
Prosetta Biosciences Raises USD31 Million in Series D Private Placement 269
Debt Offering 270
Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For US$593.5 Million 270
Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For US$593.5 Million 271
Takeda Pharma Completes Private Placement Of Notes Due 2015 For US$1,500 Million 272
Takeda Pharma Completes Private Placement Of Notes Due 2017 For US$1,500 Million 274
Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For US$870 Million 276
Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For US$745 Million 277
Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For US$745 Million 278
Asset Transactions 279
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 279
Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 281
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 282
Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 284
Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For US$65 Million 285
CSL Behring Acquires Tachosil from Takeda Nycomed 286
Acquisition 287
Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 287
Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 288
Takeda America Completes Acquisition Of Inviragen For US$250 Million 289
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 291
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 293
Takeda Pharma Invests US$5 Million In Advinus Therapeutics 296
Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To US$265 Million 298
Takeda America Completes Acquisition Of URL Pharma For US$800 Million 300
Takeda Completes Acquisition Of Intellikine For US$310 Million 302
Takeda Pharma Completes Acquisition Of Nycomed International For US$13,681 Million 305
Nycomed Completes Acquisition Of Laboratorios Farmacol 309
Merck Terminates Sale Of Its Stake In Organon BioSciences 310
Takeda Pharma Acquires Remaining 25% Stake In Tianjin Takeda From Tianjin Lisheng 312
Nycomed Acquires 51.34% Stake In Guangdong Techpool Bio-Pharma 313
Takeda Pharmaceutical Company Limited - Key Competitors 315
Key Employees 316
Locations And Subsidiaries 318
Head Office 318
Other Locations & Subsidiaries 318
Appendix 327
Methodology 327
About GlobalData 327
Contact Us 327
Disclaimer 327List of Tables
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 14
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 15
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 16
Takeda Pharmaceutical Company Limited, Deals By Therapy Area, 2010 to YTD 2016 17
Takeda Pharmaceutical Company Limited, Medical Devices Deals, 2010 to YTD 2016 19
Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 20
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 40
Wako Pure Chemical Industries Acquires Kalypsys System Business Unit Of Kalypsys 41
Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 42
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 43
Cortexyme Raises USD15 Million in Series A Financing Round 45
Univercells Raises USD3.4 Million in Equity Financing Round 47
Encycle Therapeutics Raises USD2 Million in Seed Financing 48
Presage Biosciences Raises Funds through Venture Financing 49
Naurex Raises USD80 Million in Series C Venture Financing 50
Naurex Raises US$25 Million In Venture Financing 52
Hookipa Biotech Raises US$27 Million In Series B Financing 54
Heptares Therapeutics Raises US$21 Million In Series B Financing 56
Redwood Bioscience Raises US$8.6 Million In Venture Financing 58
Naurex Raises US$38 Million In Series B Financing 59
ArmaGen Technologies Raises US$17 Million In Series A Financing 62
Juventas Therapeutics Raises US$22.2 Million In Series B Venture Financing Round 64
LigoCyte Pharmaceuticals Raises US$2 Million In Venture Financing Round 66
Redwood Bioscience Secures Funding From Takeda Ventures 67
LigoCyte Pharma Secures US$5.5 Million In Venture Financing 68
Naurex Secures US$18 Million In Series A Financing Round 69
Fate Therapeutics Secures Venture Financing 71
CellCentric Raises Funds in Series B Financing Round 73
LigoCyte Pharma Raises US$6.5 Million In Venture Financing 74
Domainex Secures Additional Financing 75
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 76
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 77
Pfizer Japan Terminates Distribution Agreement with Takeda Pharma for Prevenar13 and Benefix 78
Takeda Pharma to Enter into Agreement with Altos Therapeutics 79
Exosome Diagnostics Enters into Agreement with Takeda Pharma 80
TB Alliance and Takeda Pharma Enter into Agreement 81
Takeda Pharma Enters into Agreement with M2Gen 82
Takeda Pharma to Enter into Co-Development Agreement with Ultragenyx Pharma 83
Takeda Pharma Forms Joint Venture with Roivant Sciences 84
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 85
Prosetta Biosciences Enters into Agreement with Takeda Pharma 87
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 88
Teva Pharma and Takeda Pharma Form Joint Venture 89
Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 91
Mersana Therapeutics Enters into Agreement with Takeda 92
Broad Institute Genomic Services Partners with Takeda Pharma 93
Takeda Pharma Enters into Partnership with enGene 94
Takeda Pharma Enters into Research Agreement with NsGene 95
Takeda Pharma Enters into Agreement with Enterome Bioscience 96
Vipergen Enters into Agreement with Takeda Pharma 97
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 98
Takeda Pharma Enters into R&D Agreement with Cour Pharma 99
University College London Enters into Research Agreement with Takeda Pharma 100
Takeda Pharma Enters into Agreement with Nanotherapeutics 101
DNDi Enters into Agreement with Takeda Pharma 102
Takeda Pharma Enters into Agreement with Sanford-Burnham 103
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 104
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 105
CiRA Enters into Co-Development Agreement with Takeda Pharma 106
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 107
Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 108
Mersana Expands Co-Development Agreement with Takeda Pharma 109
Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 110
Presage Biosciences Expands its Research Agreement with Takeda Pharma 111
GE Healthcare Enters into R&D Agreement with Takeda Pharma 112
Intra-Cellular Therapies Terminates Co-Development Agreement with Takeda Pharma 113
GVK Biosciences Forms Joint Venture with Takeda Pharma 114
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 115
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 116
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 117
Mersana Therapeutics Expands Agreement with Takeda Pharma 119
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 120
Takeda Enters into R&D Agreement with University College London 122
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 123
Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 124
Santhera Pharma Terminates Co-Marketing Agreement With Takeda Pharma For Catena 125
Takeda Pharma Enters Into Distribution Agreement With Taisho Pharma 127
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 128
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 129
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 131
Scripps Research Institute Expands Research Agreement With Takeda 132
Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 133
Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 135
Gladstone Enters into Research Agreement with Takeda Pharma 137
Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 138
Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 139
Takeda Pharma Enters Into Research Agreement With BC Cancer Agency 140
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 141
Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 142
Yokogawa Electric Enters Into Co-Marketing Agreement With Wako Pure Chemical Industries For CellVoyager CV7000 143
Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 144
Metabolon Enters Into Co-Development Agreement With Takeda Pharma 145
Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 146
Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 147
CIC bioGUNE Enters into Agreement with Millennium Pharma 148
Takeda Pharma Enters Into Research Agreement With Osaka University 149
Interprotein Enters Into Co-Development Agreement With Takeda Pharma 150
Takeda Pharma International Terminates Co-Promotion Agreement With Merck For Daxas 151
Nycomed Enters Into Co-Marketing Agreement With Orion For Easyhaler 152
Eli Lilly Enters Into Co-Marketing Agreement With Takeda Pharma For Evista 154
Cellectis Bioresearch Enters Into Distribution Agreement With Wako Pure Chemical 156
Nycomed Enters Into Co-Marketing Agreement With Almirall 157
Nycomed Enters Into Distribution Agreement With Almirall, Anika, Bionorica, CSL And Helsinn 158
Dimerix Enters Into Second Research Agreement With Takeda Cambridge 160
Takeda Pharma Enters Into Research Collaboration With Samyang 161
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 162
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 164
KINAXO Biotechnologies Extends Its Collaboration With Takeda San Diego 165
Takeda Enters Into Co-Development Agreement With Covance 166
Takeda Enters Into Co-Development Agreement With Quintiles 167
Pfizer Japan Enters Into Co-Promotion Agreement With Takeda Pharma 168
Pfizer Japan Extends Co-Promotion Agreement With Takeda Pharma 170
Mitsubishi Tanabe Pharma Terminates Its Co-Development Agreement With Nycomed International 171
Evotec Enters Into Collaboration With Takeda Cambridge 172
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 173
Takeda Pharma Enters Into Research Agreement With Sanford-Burnham Medical Research Institute And Florida Hospital 174
Takeda Enters Into Research Agreement With Sage Bionetworks 176
Millenium: The Takeda Oncology Enters Into Research Collaboration With Therasis 177
Takeda Pharma Enters Into Research Agreement With Envoy Therapeutics 178
Takeda Pharma Enters into Co-Development Agreement with Orexigen Therapeutics for Contrave 179
Essen BioScience Enters Into Collaboration Agreement With Nycomed 180
CanBas Terminates Co-Development Agreement With Takeda Pharma 181
Sussex Research Labs Enters Into Distribution Agreement With Wako Pure Chemical Industries For Glycoreagents 183
Nycomed Enters Into Co-Development Agreement With Immuron 184
BC Cancer Agency And Vancouver Prostate Enter Into Agreement With Takeda Pharma 185
Takeda Pharma Enters Into Co-Promotion Agreement With Janssen Pharma 186
Nycomed International Management Enters Into Distribution Agreement With Vifor Pharma For Intravenous Iron Products 188
Nycomed Enters Into Co-Marketing Agreement With Merck 189
Nycomed Enters Into Co-Promotion Agreement With Merck 190
Dimerix Bioscience Enters Into Research Agreement With Takeda Cambridge 192
Takeda Enters Into Co-Marketing Agreement With Janssen Pharma And Janssen Pharmaceutica 193
Aska Pharma Enters Into Co-Marketing Agreement With Nihon Pharma For Minclea 195
NextGen Sciences Enters Into Agreement With Takeda Pharma 196
Ayanda Enters Into Distribution Agreement With Nycomed For CONCORDIX 197
Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 198
Takeda Pharma to Enter into Licensing Agreement with Theravance Biopharma for TD-8954 200
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 201
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 202
Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 203
Takeda Pharma Enters into Licensing Agreement with Gencia 204
Takeda Pharma Enters into Licensing Agreement with Kaketsuken 205
Dainippon Sumitomo Pharma to Terminate Licensing Agreement With Takeda Pharma for Lurasidone 206
Takeda Enters into Licensing Agreement with ImmunoGen 208
Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 209
AMAG Pharma Terminates Licensing Agreement with Takeda Pharma for Ferumoxytol 210
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 212
Mersana Exercises Option for License Agreement with Millennium 213
Sucampo Pharma Expands Licensing Agreement with Takeda Pharma 214
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 216
Takeda Pharma Terminates Licensing Agreement with Affymax for Omontys 218
Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 219
Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 220
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 221
Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 223
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 225
Immunomedics Terminates Licensing Agreement With Nycomed For Veltuzumab 227
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 228
Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 230
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 231
Takeda Pharma Terminates Licensing Agreement With Amylin Pharma To Develop Compounds For Obesity 233
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 234
Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 235
Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 236
Galaxy Biotech Terminates Licensing Agreement With Takeda Pharma For HuL2G7 237
Nycomed International Terminates Licensing Agreement With DURECT For POSIDUR 238
Nycomed Enters Into Licensing Agreement With Almirall For Ebastine 240
Nycomed Enters Into Licensing Agreement With Norgine For MOVIPREP 241
Nycomed Enters Into Licensing Agreement With Orion For Easyhaler 243
Takeda Expands Licensing Agreement With Genedata For Proteomics And Metabolomics Experiments 245
Nycomed Enters Into Licensing Agreement With F. Hoffmann-La Roche For Bonviva 246
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 247
Millennium Enters Into Licensing Agreement With Sunesis Pharma 248
Dainippon Sumitomo Enters Into Licensing Agreement With Takeda For Ceftaroline Fosamil 250
Seattle Genetics Extends Licensing Agreement With Millennium 252
DURECT Amends Licensing Agreement With Nycomed 253
Eurand Enters Into Licensing Agreement With Nycomed For ZENPEP 255
Baxter International Expands Its Licensing Agreement With Takeda Pharma 257
Japan Health Sciences Enters into Licensing agreement with Takeda for Human Papillomavirus Vaccine 259
Baxter Enters Into Licensing Agreement With Takeda 260
Nycomed Expands Its Licensing Agreement With Immuron 261
Nycomed Enters Into Licensing Agreement With Immuron 262
Ranbaxy Enters Into Licensing Agreement With Takeda 263
CellCentric Enters Into Licensing Agreement With Takeda Pharma 264
DURECT Amends Development And License Agreement With Nycomed 265
Ultragenyx Pharma to Raise up to USD65 Million in Private Placement of Shares 266
Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 268
Prosetta Biosciences Raises USD31 Million in Series D Private Placement 269
Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For US$593.5 Million 270
Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For US$593.5 Million 271
Takeda Pharma Completes Private Placement Of Notes Due 2015 For US$1,500 Million 272
Takeda Pharma Completes Private Placement Of Notes Due 2017 For US$1,500 Million 274
Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For US$870 Million 276
Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For US$745 Million 277
Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For US$745 Million 278
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 279
Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 281
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 282
Dr. Kade Pharma Acquires Portfolio
